Skip to content
10-Q

Quarterly Report

CUMBERLAND PHARMACEUTICALS INC CPIX

0001087294-26-000049

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 5, 2026 14.98M sh
Shares Diluted Q1 2025 · Mar 31, 2026 14.96M sh
Shares Diluted Q1 2025 · Mar 31, 2025 15.26M sh
Stock Repurchased Q1 2025 · Mar 31, 2026 $61K
Stock Repurchased Q1 2025 · Mar 31, 2025 $245.87K
Capex Q1 2025 · Mar 31, 2026 $0
Capex Q1 2025 · Mar 31, 2025 $47.63K
Operating Cash Flow Q1 2025 · Mar 31, 2026 $387.03K
Operating Cash Flow Q1 2025 · Mar 31, 2025 $3.9M
Cash And Equivalents Q1 2025 · Mar 31, 2026 $11.01M
Cash And Equivalents Q1 2025 · Dec 31, 2025 $11.44M
Stockholders Equity Q1 2025 · Mar 31, 2026 $21.64M
Stockholders Equity Q1 2025 · Dec 31, 2025 $24.88M
Current Liabilities Q1 2025 · Mar 31, 2026 $34.49M
Current Liabilities Q1 2025 · Dec 31, 2025 $36.74M
Total Liabilities Q1 2025 · Mar 31, 2026 $49.69M
Total Liabilities Q1 2025 · Dec 31, 2025 $52.28M
Current Assets Q1 2025 · Mar 31, 2026 $32.79M
Current Assets Q1 2025 · Dec 31, 2025 $37.06M
Total Assets Q1 2025 · Mar 31, 2026 $71M
Total Assets Q1 2025 · Dec 31, 2025 $76.82M
Eps Diluted Q1 2025 · Mar 31, 2026 −$0.22
Eps Diluted Q1 2025 · Mar 31, 2025 $0.08
Eps Basic Q1 2025 · Mar 31, 2026 −$0.22
Eps Basic Q1 2025 · Mar 31, 2025 $0.08
Sga Expense Q1 2025 · Mar 31, 2026 $2.55M
Sga Expense Q1 2025 · Mar 31, 2025 $2.46M
Rd Expense Q1 2025 · Mar 31, 2026 $1.46M
Rd Expense Q1 2025 · Mar 31, 2025 $1.3M
Net Income Q1 2025 · Mar 31, 2026 −$3.29M
Net Income Q1 2025 · Mar 31, 2025 $1.26M
Operating Income Q1 2025 · Mar 31, 2026 −$3.13M
Operating Income Q1 2025 · Mar 31, 2025 $1.29M
Cost Of Revenue Q1 2025 · Mar 31, 2026 $1.93M
Cost Of Revenue Q1 2025 · Mar 31, 2025 $1.43M
Revenue Q1 2025 · Mar 31, 2026 $9.13M
Revenue Q1 2025 · Mar 31, 2025 $11.71M